Skip Navigation

European Journal of Echocardiography 2005 6(2):79-82; doi:10.1016/j.euje.2005.01.001
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Eur J Echocardiogr
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Senior, R.
Right arrow Articles by Ashrafian, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Senior, R.
Right arrow Articles by Ashrafian, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2005, The European Society of Cardiology

Screening for isolated diastolic dysfunction – a bridge too far?

Roxy Senior* and Houman Ashrafian

Department of Cardiovascular Medicine, Northwick Park Hospital, Watford Road, Harrow, Middlesex, HA1 3UJ, UK

roxy.senior@virgin.net

* Corresponding author: Tel.: +44 208 869 2548; fax: +44 208 864 0075.

The first 10% of the full text of this article appears below.

Please see page 85 for the article by Nielsen et al. (doi: 10.1016/j.euje.2004.07.004) to which this editorial pertains.


   Introduction
 
Advances in our ability to reduce the immediate mortality associated with acute coronary syndrome and hypertension have resulted in an inexorable increase in chronic myocardial dysfunction. In the United Kingdom ~2% of the population have left ventricular systolic dysfunction (LVSD), which develops with an incidence of 10 per 1000 among persons older than 65 and is expanding in absolute terms with the demographic transition.1 The mortality of heart failure approaches 50% for patients with NYHA Class IV symptoms.2 Notable advances in the treatment of LVSD have resulted from widespread implementation of pharmacological, revascularisation, device and rehabilitation therapies; this is especially true if treatment is initiated early in the disease. An inevitable next step is therefore to extend and translate the successes of LVSD to identifying and treating its . . . [Full Text of this Article]


   What is the pathophysiological basis of diastolic heart failure?
 

   What is the evidence that diastolic heart failure contributes to ill-health
 

   How is LVDD most effectively identified?
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Eur J Echocardiogr:

Value of left ventricular filling parameters to predict mortality and functional class in patients with heart disease from the community
Olav Wendelboe Nielsen, Ahmad Sajedieh, Frants Petersen, and Jørgen Fischer Hansen
Eur J Echocardiogr 2005 6: 85-91. [Abstract] [FREE Full Text]